Tokyo -- Terumo Corporation (TSE: 4543 Section 1) and Biosensors International Group, Ltd. ("Biosensors", Bloomberg: BIG SP; Reuters: BIOS.SI; SGX: B20) announced today an expansion of sales collaboration in Japan and an extension of their existing licensing agreements, in regard to Terumo's Nobori® drug-eluting stent.
Through an expansion of existing sales collaboration with Biosensors Japan Co., Ltd., Japanese subsidiary of Biosensors, Terumo will aim to expand the sales of Nobori® drug-eluting stent. On another front, under the agreements, Terumo can continue to sell Nobori® for territories outside of Japan, excluding the United States, until December 2016.
Terumo plans to launch its "Ultimaster™" Silorimus drug-eluting stent from June 2014, which has already received the CE mark. By also selling "Ultimaster™," Terumo aims to achieve growth and expand the company's drug-eluting stent business.
Nobori® incorporates Biolimus A9™ anti-restenotic drug and biodegradable polymer developed and patented by Biosensors. It is now sold in over 20 countries across Europe, Asia and Latin America.
Terumo (TSE: 4543) is a global leader in medical technology and has been committed to “Contributing to Society through Healthcare” for 100 years. Based in Tokyo and operating globally, Terumo employs more than 28,000 associates worldwide to provide innovative medical solutions in more than 160 countries and regions. The company started as a Japanese thermometer manufacturer, and has been supporting healthcare ever since. Now, its extensive business portfolio ranges from vascular intervention and cardio-surgical solutions, blood transfusion and cell therapy technology, to medical products essential for daily clinical practice such as transfusion systems, diabetes care, and peritoneal dialysis treatments. Terumo will further strive to be of value to patients, medical professionals, and society at large.